|Bid||1.5200 x 1000|
|Ask||1.5400 x 1200|
|Day's range||1.5000 - 1.5700|
|52-week range||1.5000 - 10.7000|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||N/A|
|Earnings date||01 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.00|
Lannett (LCI) delivered earnings and revenue surprises of -8.00% and 2.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Good afternoon, everyone, and thank you for joining us today to discuss Lannett Company's fiscal 2022 first quarter financial results. On the call today are Tim Crew, Chief Executive Officer; John Kozlowski, the company's Chief Financial Officer; Maureen Cavanaugh, our Chief Commercial Operations Officer; and Steve Lehrer, who leads our biosimilar insulin initiatives.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.